Veracyte Stock Price, News & Analysis

Veracyte (NASDAQ:VCYT) has completed enrollment for its NIGHTINGALE clinical utility trial, evaluating the Percepta Nasal Swab test for lung cancer detection. The trial has successfully enrolled 2,400 patients across 90+ centers in the United States.

The prospective, randomized, blinded trial will follow patients for up to two years to assess the test's ability to reduce unnecessary procedures for benign nodules and accelerate treatment for cancerous ones. The Percepta Nasal Swab test has demonstrated strong clinical validation results, showing 97% sensitivity with 40% specificity for low-risk nodules and 92% specificity with 57% sensitivity for high-risk nodules.

Veracyte (NASDAQ:VCYT) reported strong Q2 2025 financial results with total revenue growing 14% year-over-year to $130.2 million. Testing revenue increased 14% to $122.3 million, driven by exceptional performance of Decipher tests, which achieved a 28% volume growth. The company recorded a GAAP net loss of $1.0 million, including $20.5 million in one-time impairment charges related to French subsidiary restructuring.

Key highlights include Decipher revenue growth of 24% to $76.3 million and Afirma revenue increase of 5% to $43.4 million. The company generated $33.6 million in operating cash flow and ended the quarter with $320.7 million in cash and equivalents. Following strong performance, Veracyte raised its full-year 2025 testing revenue guidance to $477-483 million and adjusted EBITDA margin guidance to 23.5%.

Veracyte (NASD: VCYT) is set to join the S&P SmallCap 600 index effective prior to market opening on July 29, 2025. The company will replace Triumph Group (NYSE: TGI), which is being acquired by Warburg Pincus LLC and Berkshire Partners LLC.

The index change comes as Triumph Group's acquisition is expected to close soon, pending final conditions. Veracyte will be added to the Health Care sector of the index, while Triumph Group will be removed from the Industrials sector.

Veracyte (NASDAQ:VCYT), a cancer diagnostics company, has scheduled its second quarter 2025 financial results release for August 6, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update.

Investors can access the live webcast through the company's website, and a replay will be available at the investor relations section. Conference call participation requires pre-registration through the provided link.

Veracyte (NASDAQ:VCYT) announced that three research abstracts utilizing their Afirma GRID database will be presented at ENDO 2025, the annual Endocrine Society meeting, taking place July 12-15 in San Francisco.

The presentations will focus on various aspects of thyroid cancer research, including vitamin D signaling expression markers, cell cycle progression scoring for prognosis prediction, and retinoic acid receptor expression in thyroid tumors. All three posters will be presented on Monday, July 14, from 12:00-1:30 p.m. PT at the Moscone Convention Center.

The research demonstrates the capabilities of Veracyte's whole-transcriptome-based Afirma GRID research tool in advancing the understanding of thyroid cancer at the molecular level, supporting the company's mission to enable personalized cancer care.

Veracyte (VCYT) announced the presentation of eight abstracts featuring data from its Decipher Prostate and Bladder genomic classifiers at the upcoming ASCO meeting. Key findings from the STAMPEDE trial showed that metastatic prostate cancer patients with PTEN-inactive gene signatures had a 43% reduced risk of death when adding docetaxel to standard ADT therapy, while PTEN-active patients showed no benefit. The study followed 832 patients for 14 years. Additionally, the SURE-02 Phase 2 study revealed promising results for bladder cancer patients, demonstrating that neoadjuvant Sacituzumab Govitecan plus Pembrolizumab treatment was safe and effective for muscle-invasive bladder cancer (MIBC). The research utilized Veracyte's Decipher GRID platform, showing associations between Luminal subtype and clinical complete response, potentially enabling more personalized treatment approaches.

Veracyte (NASDAQ: VCYT), a cancer diagnostics company, has announced its participation in two upcoming investor conferences in June 2025. The company will present at the William Blair 45th Annual Growth Stock Conference in Chicago on June 3rd at 5:40 p.m. ET, followed by a presentation at the Jefferies Global Healthcare Conference in New York on June 4th at 2:00 p.m. ET.

Live audio webcasts will be accessible through Veracyte's investor relations website, with replays available for 90 days following each presentation.

Veracyte (NASDAQ: VCYT) reported strong Q1 2025 financial results with total revenue reaching $114.5 million, up 18% year-over-year. The company achieved its eleventh consecutive quarter of 20%+ testing volume growth, primarily driven by Decipher and Afirma tests. Key highlights include:

- Testing revenue increased 19% to $107.3 million - Total testing volume grew 22% to 40,655 tests - Decipher revenue surged 33% to $66.6 million - Net income reached $7.0 million (6.2% of revenue) - Adjusted EBITDA was $24.7 million (21.6% of revenue)

The company maintained its 2025 testing revenue guidance of $470-480 million (12-15% growth) and raised adjusted EBITDA margin guidance to 22.5%. Additionally, Veracyte announced plans to discontinue funding its French subsidiary, with court proceedings expected to complete by end of 2025.

Veracyte (VCYT) has announced the expansion of its Decipher Prostate test to include patients with metastatic prostate cancer. The test, previously used only for localized disease, is now the only gene expression test covered by Medicare for treatment decisions across all prostate cancer risk levels.

The company will initially offer the Decipher Prostate Metastatic Genomic Classifier through an early access program at select clinical sites, with broader availability planned for June 2025. The test's clinical validity and utility have been validated through multiple Phase 3 clinical studies, demonstrating its ability to identify patients with more-aggressive tumor biology through high Decipher scores.

With approximately 30,000 metastatic prostate cancer cases diagnosed annually in the US (10% of all cases), this expansion addresses a significant medical need. The test aims to help clinicians determine which patients are likely to benefit from available treatments and which may avoid unnecessary toxic side effects.